SI-BONE
SIBN | NASDAQ
$23.41
-$0.03 (-0.13%)
At close: Nov 16, 2026, 4:00 PM ET
$23.41
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
SI-BONE Company Profile
Company profile explainedCompany Profile
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Key Executives
| Name | Position |
|---|---|
| Laura A. Francis | Chief Executive Officer & Director |
| Scott A. Yerby | Senior Vice President of Engineering & Chief Technology Officer |
| Anshul Maheshwari | COO & CFO |
| Anthony J. Recupero | Advisor |
| Daniel Joseph Cher | Senior Vice President of Clinical, Regulatory Affairs & Quality |
| Ian Bailey | Vice President of Product & Marketing |
| Jeffrey W. Dunn | Executive Chairman |
| Michael A. Pisetsky | Chief Business & Legal Affairs Officer, Secretary and General Counsel |
| Nikolas F. Kerr | Chief Commercial Officer |
| Saqib Iqbal | Vice President of Financial Planning & Analysis and Investor Relations |
| W. Carlton Reckling | Chief Medical Officer & Vice President of Medical Affairs |
SI-BONE
| Country | United States |
| IPO Date | Oct 17, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 376 |
| CEO | Laura A. Francis |
Contact Details
471 El Camino Real Santa Clara,
California 95050 United States
Stock Details
| Ticker Symbol | SIBN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001459839 |
| CUSIP Number | 825704109 |
| ISIN Number | US8257041090 |
| SIC Code | 3841 |
Recent News
- 4 days ago / zacks.comAre You Looking for a Top Momentum Pick? Why Si-Bone (SIBN) is a Great Choice
- 6 days ago / seekingalpha.comSI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript
- 12 days ago / zacks.comSiBone (SIBN) Hit a 52 Week High, Can the Run Continue?
Add to Watchlist
Select watchlists to add or remove SIBN